05/11/2020 - General information
The ICOD (Improving Cognition in Down Syndrome) project is being coordinated by the Integrated Pharmacology and Systems Neuroscience Research Group, led by Dr. Rafael de la Torre. It will trial a new therapy to treat cognitive deficits in Down Syndrome sufferers. Six institutions from Spain, France and Italy are taking part. A project led by the Hospital del Mar Medical Research Institute (IMIM), has received a six million euro development grant from the European Commission. The Improving Cognition in Down Syndrome (ICOD) project was one of 75 projects selected within the European Union's Horizon 2020 research and innovation programme. Only nine projects coordinated by Catalan organisations will benefit from these grants, in the last year they are being awarded.
03/11/2020 - Covid-19
Some of the principal treatments for osteoporosis, denosumab, zoledronate and calcium, could have a protective effect against COVID-19 in patients who take them, specifically a 30 to 40% reduction in the rate of infection, according to the results of a joint study by Hospital del Mar, the Hospital del Mar Medical Research Institute (IMIM), Pompeu Fabra University and the Pere Virgili Health Park. The study, the first of its kind in the world, has just been published the journal Aging. The last author of the study, Dr. Jordi Monfort, head of Rheumatology at Hospital del Mar and coordinator of the Cell Research on Inflammation and Cartilage research group at Hospital del Mar-IMIM, explains that "there are indications to allow hypothesizing that certain drugs used to treat rheumatic diseases could interfere positively in the natural history of COVID-19, either by decreasing its incidence or by decreasing its progression to more serious cases". The study analysed data from more than 2,000 patients with osteoporosis, osteoarthritis and fibromyalgia and their relationship with COVID-19 infection who are being followed up at Hospital del Mar and in the Mar Health Park healthcare sphere of influence.
29/10/2020 - Press release
The Hospital del Mar Medical Research Institute (IMIM), together with the INCLIVA Health Research Institute, from Hospital Clínic in Valencia, and the Vall d'Hebron Institute of Oncology, have obtained funding from the Spanish Association Against Cancer (AECC) for their project entitled Factors derived from the tumoral microenvironment in localised colon cancer: clinical impact and therapeutic implications. Dr. Clara Montagut, head of the Gastrointestinal Cancer Unit in the Medical Oncology Service at Hospital del Mar, coordinator of the Clinical and Translational Research Group on new therapies and biomarkers in colon and rectal cancer at the Hospital del Mar Medical Research Institute (IMIM) and a participant in the study, points out that "The goal of this research is to identify markers that will help us determine whether the cancer will re-emerge in a patient who has undergone colon cancer surgery. This is extremely important for people who have colon cancer, since at present we are unable to predict whether the tumour will reappear or not after surgery.
27/10/2020 - Press release
A team of researchers from the Germans Trias i Pujol Hospital and Research Institute (IGTP) and the Hospital del Mar Medical Research Institute (IMIM) has shown that regularly consuming foods rich in omega-3 fatty acids, from both animal and vegetable origins, strengthens the heart's membranes and helps improve the prognosis in the event of a myocardial infarction. To arrive at these conclusions, they used data from 950 patients. The omega-3 levels in the blood of these individuals were determined when they were admitted to hospital to be treated for the heart attack. This measurement indicates, very accurately, how much of these fats the patients had eaten in the weeks prior to the sampling, in other words, before the heart attack. The patients were monitored for three years after being discharged, and the researchers observed that having high levels of omega-3 in the blood at the time of the infarction, which had been consumed in the weeks leading up to the heart attack, was associated with a lower risk of complications. The results of the study have just been published in the prestigious Journal of the American College of Cardiology.
17/10/2020 - General information
The PRBB and its centres are preparing the next edition of the Open Day. As always, we will be holding our science outreach party for the whole family in October, organised with the support of the park's volunteers. But everything else will be different! The current situation means we are unable to organise a face-to-face celebration, so on this occasion our Open Day events will be 100% virtual. And we have a week full of activities to enjoy from home, with your family and friends or at your educational centre.
Més informació "Open Day at the PRBB - From 26th to 31st October"
19/10/2020 - Press release
Last Friday, the FERO Foundation announced the winners of the 19th FERO Grants and the winner of the 2nd FERO-Mango Breast Cancer Research Project. The grants, worth €80,000 each, are intended to help young researchers develop their translational cancer research projects over a two-year period. "It is expected that 277,394 people will be diagnosed with cancer before the end of 2020. We cannot allow the pandemic scenario in which we find ourselves to detract from the treatment and survival opportunities of the thousands of patients who are currently struggling with cancer. That is why at FERO we are doing everything we can to ensure that COVID-19 affects doctors and patients as little as possible, and that resources continue to reach researchers and centres. One way of achieving this is by continuing to support projects through our grants", explains Sol Daurella, president of the institution.
16/10/2020 - General information
Dr Robert Güerri, section chief of the Infectious Diseases Service at Hospital del Mar and a researcher in the Infectious Pathology and Antimicrobial Research Group at the Hospital del Mar Medical Research Institute (IMIM), has received a Young Researcher Award from the SI 2020 Symposium, organised by the pharmaceutical company Janssen. The aim of this initiative is to promote the investigative work of young researchers, whose careers have made significant scientific and technical contributions in the field of HIV. The symposium, which should have been held in March, had to be cancelled due to the COVID-19 pandemic.
Més informació "SI 2020 Symposium Young Researcher Award presented to Dr. Robert Güerri"
15/10/2020 - Press release
They believe that the treatment currently used in many cases, based solely on short-acting bronchodilators like the well-known Ventolin, may increase the risk of severe asthma attacks. This is revealed by a study published in the journal Archivos de Bronconeumología. They advocate the use of inhaled corticoids, which is also the treatment recommended by the international Global Initiative for Asthma (GINA). Asthma is increasingly prevalent and affects 5-10% of the general population. Unfortunately, the decline in associated mortality has slowed in recent years. In the current context, characterised by the COVID-19 epidemic, there is no evidence that suffering asthma implies a more severe form of COVID-19.
14/10/2020 - Press release
Chemotargets, a global leader in predictive analytics solutions for the pharma and biotech sector, has appointed Dr. Scott Boyer as new CEO with the aim to consolidate its transition from a software business to a key player in the biotech sector. Dr Boyer joins Chemotargets from Swedish drug development company Klaria, where he has been CEO/CSO since 2015 and will continue as a member of the Board of Directors and as a scientific advisor. Prior to joining Klaria, he was Chief Scientist at AstraZeneca (Sweden), with global responsibility for molecular and investigational toxicology across the company, and a member of the company's senior management team. Prior to AstraZeneca, Dr. Boyer was a senior scientist at Pfizer Central Research in the US.
Més informació "Dr. Scott Boyer joins Chemotargets as new CEO"
08/10/2020 - Press release
Doing 150 minutes of moderate-intensity physical activity (fast walking or dancing, for example) or 75 minutes of vigorous activity (running or other sports) a week, as recommended by the World Health Organisation (WHO), reduces your mortality risk by 16%. At the same time, cardiovascular mortality risk drops by 27% and cardiovascular event risk falls by 12%. This is highlighted in a study published by the Revista Española de Cardiología led by doctors from Hospital del Mar and researchers from the Hospital del Mar Medical Research Institute (IMIM), the University of Vic-Central Catalonia (UVic- UCC), and the CIBERCV and CIBERESP. The work also reveals that doing three to five times more physical activity than the recommended amount maximises the benefit.
Més informació "Following physical activity recommendations can reduce mortality risk by 16%"
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
